Relapsed Acute Myelogenous Leukemia (AML)
Also known as: Acute Myeloid Leukemia, in Relapse / Acute, relapsed Myeloid Leukemia / Relapsed AML / Relapsed Acute Myeloid Leukemia (AML) / Relapsed Acute Myeloid Leukemia / Relapsed Acute Myelogenous Leukemia / Acute, relapsed Myelogenous Leukemia / Acute Myeloid Leukemia (AML) Relapse / Acute Myelogenous Leukemia in Relapse / Myeloid Leukemia in Relapse (Disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB13874 | Enasidenib | An isocitrate dehydrogenase-2 inhibitor used to treat relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. |
| DB00056 | Gemtuzumab ozogamicin | A monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. |
| DB12141 | Gilteritinib | An AXL receptor tyrosine kinase inhibitor used to treat relapsed or refractory acute myeloid leukemia. |
| DB14568 | Ivosidenib | An isocitrate dehydrogenase-1 inhibitor used to treat acute myeloid leukemia and cholangiocarcinoma in adults with a susceptible IDH1 mutation. |
| DB16267 | Olutasidenib | An isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as detected by an FDA-approved test. |